前列腺特异性抗原(PSA)检测筛查前列腺癌:系统评价与Meta分析
该系统评价与Meta分析纳入5项随机对照试验、共721718名无前列腺癌诊断的男性,比较PSA筛查与常规诊疗。全组分析显示筛查可能对全因死亡率无影响(IRR 0.99,95%CI 0.98-1.01;中等确定性),可能对前列腺癌特异性死亡率无影响(IRR 0.96,95%CI 0.85-1.08;低确定性)。低偏倚风险研究(n=1)敏感性分析显示筛查似乎对全因死亡率无影响(IRR 1.0,95%CI 0.98-1.02;中等确定性),但可能对前列腺癌特异性死亡率有微小影响(IRR 0.79,95%CI 0.69-0.91;中等确定性),相当于每1000名男性筛查10年减少1例前列腺癌死亡。模型估计每1000名男性筛查,约分别增加1、3、25例因脓毒症住院、需尿垫处理尿失禁和报告勃起功能障碍。
要点
- 全组分析:PSA筛查可能对全因死亡率无影响(IRR 0.99,95%CI 0.98-1.01;中等确定性)。
- 全组分析:PSA筛查可能对前列腺癌特异性死亡率无影响(IRR 0.96,95%CI 0.85-1.08;低确定性)。
- 低偏倚风险研究(n=1)敏感性分析:筛查似乎对全因死亡率无影响(IRR 1.0,95%CI 0.98-1.02;中等确定性),但可能对前列腺癌特异性死亡率有微小影响(IRR 0.79,95%CI 0.69-0.91;中等确定性),相当于每1000名男性筛查10年减少1例前列腺癌死亡。
- 模型估计每1000名男性筛查,约分别增加1、3、25例因脓毒症住院、需尿垫处理尿失禁和报告勃起功能障碍。
- 临床医生和患者在考虑PSA筛查时需权衡上述获益与筛查的潜在短期和长期危害,包括活检及后续治疗并发症、过度诊断和过度治疗风险。
适用人群与场景
- 无前列腺癌诊断的男性。
研究设计与关键结果
- 研究设计:系统评价与Meta分析,纳入5项随机对照试验,共721718名无前列腺癌诊断的男性,比较PSA筛查与常规诊疗。
- 全组分析:筛查可能对全因死亡率无影响(IRR 0.99,95%CI 0.98-1.01;中等确定性),可能对前列腺癌特异性死亡率无影响(IRR 0.96,95%CI 0.85-1.08;低确定性)。
- 低偏倚风险研究(n=1)敏感性分析:筛查似乎对全因死亡率无影响(IRR 1.0,95%CI 0.98-1.02;中等确定性),但可能对前列腺癌特异性死亡率有微小影响(IRR 0.79,95%CI 0.69-0.91;中等确定性),相当于每1000名男性筛查10年减少1例前列腺癌死亡。
- 模型估计每1000名男性筛查,约分别增加1、3、25例因脓毒症住院、需尿垫处理尿失禁和报告勃起功能障碍。
- 纳入试验中关于活检和治疗相关并发症的直接比较数据有限。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,采用GRADE方法评估证据质量。
- 全因死亡率证据确定性为中等;前列腺癌特异性死亡率证据确定性为低。
- 低偏倚风险研究敏感性分析中,全因死亡率和前列腺癌特异性死亡率证据确定性均为中等。
- 局限:纳入研究在筛查频率和间隔、活检的PSA阈值以及偏倚风险方面存在差异。
- 局限:纳入试验中关于活检和治疗相关并发症的直接比较数据有限。
对床旁实践的改变
- 临床医生和患者在考虑基于PSA的筛查时,需权衡前列腺癌特异性死亡率的微小获益与筛查的潜在短期和长期危害,包括活检及后续治疗并发症、过度诊断和过度治疗风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials comparing PSA screening with usual care in men without a diagnosis of prostate cancer.
DATA EXTRACTION: At least two reviewers screened studies, extracted data, and assessed the quality of eligible studies. A parallel guideline committee (BMJ Rapid Recommendation) provided input on the design and interpretation of the systematic review, including selection of outcomes important to patients. We used a random effects model to obtain pooled incidence rate ratios (IRR) and, when feasible, conducted subgroup analyses (defined a priori) based on age, frequency of screening, family history, ethnicity, and socioeconomic level, as well as a sensitivity analysis based on the risk of bias. The quality of the evidence was assessed with the GRADE approach.
RESULTS: Five randomised controlled trials, enrolling 721 718 men, were included. Studies varied with respect to screening frequency and intervals, PSA thresholds for biopsy, and risk of bias. When considering the whole body of evidence, screening probably has no effect on all-cause mortality (IRR 0.99, 95% CI 0.98 to 1.01; moderate certainty) and may have no effect on prostate-specific mortality (IRR 0.96, 0.85 to 1.08; low certainty). Sensitivity analysis of studies at lower risk of bias (n=1) also demonstrates that screening seems to have no effect on all-cause mortality (IRR 1.0, 0.98 to 1.02; moderate certainty) but may have a small effect on prostate-specific mortality (IRR 0.79, 0.69 to 0.91; moderate certainty). This corresponds to one less death from prostate cancer per 1000 men screened over 10 years. Direct comparative data on biopsy and treatment related complications from the included trials were limited. Using modelling, we estimated that for every 1000 men screened, approximately 1, 3, and 25 more men would be hospitalised for sepsis, require pads for urinary incontinence, and report erectile dysfunction, respectively.
CONCLUSIONS: At best, screening for prostate cancer leads to a small reduction in disease-specific mortality over 10 years but has does not affect overall mortality. Clinicians and patients considering PSA based screening need to weigh these benefits against the potential short and long term harms of screening, including complications from biopsies and subsequent treatment, as well as the risk of overdiagnosis and overtreatment.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number CRD42016042347.
参考来源
- Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018. PMID: 30185521. doi:10.1136/bmj.k3519
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。